What is Apotex's Ruxolitinib?
Apotex markets a generic version of ruxolitinib, a JAK1/JAK2 inhibitor approved for specific blood disorders. It matches the branded drug Jakafi (from Incyte) in indications, targeting conditions involving overactive immune responses or abnormal blood cell production.[1]
Approved Diseases for Apotex Ruxolitinib
Health Canada and other regulators have approved Apotex's ruxolitinib (e.g., 5mg, 10mg, 15mg, 20mg tablets) for:
- Intermediate or high-risk primary myelofibrosis (PMF), including post-polycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis, to reduce spleen volume and symptoms.
- Polycythemia vera (PV) in patients unresponsive to or intolerant of hydroxyurea.
- Steroid-refractory acute graft-versus-host disease (GVHD) in adults and pediatric patients 12+ years.[2][3]
How Does It Compare to Branded Jakafi?
Apotex's version is bioequivalent, with identical dosing and indications. No differences in targeted diseases; generics follow originator approvals post-patent expiry or litigation wins. Jakafi's US FDA approvals (FDA) align similarly, adding chronic GVHD later.[1][4]
Off-Label or Emerging Uses?
Ruxolitinib sees off-label investigation for ulcerative colitis, vitiligo, and certain lymphomas, but Apotex's labeling sticks to approved indications. No Apotex-specific expansions.[2]
Patent Status and Availability
Apotex gained approval after challenging Incyte's patents. Key Jakafi patents expired or settled (e.g., US 8,158,616 in 2024 for some formulations). Check DrugPatentWatch.com for expiry timelines and generics DrugPatentWatch.[5]
Sources:
[1] Health Canada Product Monograph - Apotex Ruxolitinib
[2] Apotex Product Page
[3] FDA Orange Book - Ruxolitinib Generics
[4] Incyte Jakafi Label
[5] DrugPatentWatch.com - Ruxolitinib